These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16433582)

  • 1. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome.
    Nieto JM; Pisegna JR
    Expert Opin Pharmacother; 2006 Feb; 7(2):169-75. PubMed ID: 16433582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.
    Tomassetti P; Salomone T; Migliori M; Campana D; Corinaldesi R
    Drugs Aging; 2003; 20(14):1019-34. PubMed ID: 14651442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A; Mignon M; Samoyeau R
    Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zollinger-Ellison syndrome. Diagnosis and therapy.
    Campana D; Piscitelli L; Mazzotta E; Bonora M; Serra C; Salomone L; Corinaldesi R; Tomassetti P
    Minerva Med; 2005 Jun; 96(3):187-206. PubMed ID: 16175161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitors of proton pump in the treatment of Zollinger-Ellison syndrome].
    Kubyshkin VA; Kochatkov AV
    Khirurgiia (Mosk); 2012; (12):67-71. PubMed ID: 23323285
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.
    Singh Ospina N; Donegan D; Rodriguez-Gutierrez R; Al-Hilli Z; Young WF
    Am J Med; 2017 May; 130(5):603-605. PubMed ID: 28011308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC
    Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors.
    Banasch M; Schmitz F
    Wien Klin Wochenschr; 2007; 119(19-20):573-8. PubMed ID: 17985090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
    Hirschowitz BI; Simmons J; Mohnen J
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease.
    Blonski WC; Katzka DA; Lichtenstein GR; Metz DC
    Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):441-4. PubMed ID: 15756097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
    Hirschowitz BI; Haber MM
    Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy.
    Weber HC; Venzon DJ; Jensen RT; Metz DC
    Gastroenterology; 1997 Jan; 112(1):84-91. PubMed ID: 8978346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Zollinger-Ellison syndrome with gastric antisecretory drugs.
    Bonfils S; Mignon M
    Scand J Gastroenterol Suppl; 1988; 146():111-20. PubMed ID: 3067333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.